Francis P. Worden, MD, discusses his key takeaways for other oncologists treating patients with radioidine-refractory differentiated thyroid cancer.

Lenvima (lenvatinib mesylate) was approved and launched for differentiated thyroid cancer in the US, the EU and Japan last year, and earned 1.3bn yen (around $12m) in the first quarter of 2016.

Dr. Hutson said the treatment uses Lenvatinib (Lenvima) and Pembrolizumab (Keytruda) in combination which showed promising ...

The work further solidifies the effectiveness of the lenvatinib (Lenvima) and pembrolizumab (Keytruda) combination in treating this aggressive form of kidney cancer. Hutson played a key role in ...

The FDA has granted approval to nivolumab plus ipilimumab for use in unresectable or metastatic hepatocellular carcinoma.

During a live event, Daniel M. Geynisman, MD, and participants discussed their answers to a poll on which combination to use ...

Gary Hendler, chairman and CEO of EMEA region for Eisai, talked to Richard Staines at pharmaphorum about findings of the REFLECT study and the prospects for Lenvima (lenvatinib) in liver cancer.